<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919919</url>
  </required_header>
  <id_info>
    <org_study_id>fr003</org_study_id>
    <secondary_id>5340/09</secondary_id>
    <nct_id>NCT00919919</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen</brief_title>
  <official_title>Efficacy &amp; Tolerability of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Replacement Therapy - Phase II Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to confirm that the efficacy of vaginal progesterone is at
      least as good as oral progesterone in order to protect the endometrium of uncontrolled
      proliferation and prevent endometrial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estrogen Replacement Therapy must be opposed by progesterone in order to protect the
      endometrium of uncontrolled proliferation and prevent endometrial cancer, in women with an
      intact uterus.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing the proportion of women with endometrial thickness not exceeding 8mm and change not exceeding 3mm between the two groups.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of bleeding pattern between the two groups.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To demonstrate that vaginal progesterone tablets decrease systemic progesterone adverse reactions using a questionnaire.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Endometrial Hyperplasia</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Progesterone vaginal tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Activella</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progesterone</intervention_name>
    <description>Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month</description>
    <arm_group_label>Progesterone vaginal tablet</arm_group_label>
    <other_name>Endometrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>activella</intervention_name>
    <description>Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally</description>
    <arm_group_label>Activella</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who are candidates for Hormone Replacement Therapy due to menopausal symptoms.

          -  Women with an intact uterus.

          -  No menses within the 12 months preceding screening visit and /or FSH &gt;30 IU/L.

          -  Endometrial thickness ≤ 5 mm.

        Exclusion Criteria:

          -  Submucosal fibroid/s that applying pressure and affecting endometrial thickness

          -  Other medication that could affect estrogenic state.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Kaplan, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center Beilinson Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aviva Kaplan</last_name>
    <phone>972-3-9377534</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin Medical Center Beilinson Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aviva kaplan</last_name>
      <phone>972-50-5511591</phone>
    </contact>
    <investigator>
      <last_name>Boris kaplan, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Hirsh, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravit Nahum, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dove Lazarovitz, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Avi Ninio, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yosi Maai, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan Kelman, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raia Nir, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Bloch, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yehuda Yeger, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reuven Amster, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tzvi Zehavi, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gay Gutman, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yosi Menkas, Dr'</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>1. Jennifer Blake. Menopause: evidence-based practice. Best Practice &amp; Research Clinical Obstetrics and Gynaecology. 2006;20:799-839 2. Deborah Graby: Management of Menopausal Symptoms. The NEW ENGLAND JOURNAL of MEDICINE. 2006; 355:2338-47 3. Elena M. Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms. Journal of Managed Care Pharmacy. 2008;14(3):s14-s19 4. T.Levy. Z.Ben-Refael et al. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. Human Reproduction. 1999;14(3):606-10 6. Devroey P, Palermo G, Bourgain C, et al. Progesterone administration in patients with absent ovaries. Int J Fertile. 1989;34:188- 93 7. Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertile Steril. 1985;44:622-26 8. C.Ficicioglu, B. Gurbuz, H. Canova. High local endometrial effect of vaginal progesterone gel. Gynecol Endocrinol. 2004;18:240-43 9. Steege JF, Rupp SL, Stout AL, et al. Bioavailability of nasally administered progesterone. Fertile Steril. 1986;46:722-29 10. Chakmakjian ZH, Zachariah NY. Bioavailability of progesterone with different modes of administration. J Reprod Med. 1987;32:443-48</citation>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>June 11, 2009</last_update_submitted>
  <last_update_submitted_qc>June 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Boris Kaplan</name_title>
    <organization>Gynecology Department</organization>
  </responsible_party>
  <keyword>menopause</keyword>
  <keyword>Endometrial Thickness</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

